Phesi, a leading provider of patient-centered data analytics, has enhanced its Trial Accelerator™ platform by introducing the Patient Access Score (PAS). This addition empowers clinical trial sponsors to pinpoint the most effective investigators. The PAS metric is derived from Phesi's Digital Patient Profile (DPP), utilizing real-world data from a vast pool of over 95 million patients and more than 500,000 clinical studies available on Phesi's Trial Accelerator™ platform. PAS can be utilized to optimize the selection of investigators and trial sites, reduce protocol revisions, and cut costs by avoiding the activation of underperforming sites.
PAS serves as an extension of Phesi's existing scoring and performance toolkit, enabling precision in the design of patient-centered trials. It offers detailed insights into an investigator's potential patient outreach and their historical experience with clinical trials. For the first time, PAS establishes a connection between investigator sites and the targeted patient population, ensuring that study design aligns with commercial objectives and that development programs prioritize patient-centricity.
Specifically, PAS evaluates the likelihood of an investigator site to access the patient population defined in the protocol. It does so by focusing on investigators from Trial Accelerator who contributed patients to the specific DPP used in construction. The greater the number of patient cohorts associated with a specific investigator in a DPP, the higher the likelihood that the investigator site can recruit patients in accordance with the protocol design. PAS complements a set of performance measures for investigator sites, further enhancing the predictability of Trial Accelerator for patient enrollment in clinical trials.
PAS is applicable across all indications, but it proves particularly valuable for rare diseases where patient numbers are limited. It is also beneficial for non-rare conditions with complexities such as comorbidities or a wide range of patient characteristics. For instance, despite stroke being a major global health concern, the diversity in stroke types and patient cohorts presents a challenge for study. Identifying an investigator experienced with the specific type of stroke under investigation (e.g., transient ischemic attack, ischemic or hemorrhagic stroke), who also has access to patients in the acute phase of stroke and the ability to rapidly enroll them, is a significant undertaking.
Phesi's Trial Accelerator relies on real-time, up-to-date data, ensuring that only active investigators and sites are recommended. By generating a tailored score through PAS, sponsors can efficiently activate, enroll, and collect high-quality data.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!